Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Moderna ( (MRNA) ).
Moderna has secured a tender to supply its mRNA COVID-19 vaccine to 17 countries in the European Union, Norway, and North Macedonia, providing an opportunity to diversify vaccine supply and improve vaccination campaign efficiency with pre-filled syringe formats. This agreement strengthens Moderna’s market position in Europe and supports national vaccination efforts, enhancing health security and addressing healthcare provider preferences.
More about Moderna
Moderna is a leader in mRNA medicine, focusing on the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. The company is known for its rapid advancement in creating effective COVID-19 vaccines and continues to innovate at the intersection of science, technology, and health.
YTD Price Performance: 0.93%
Average Trading Volume: 9,618,128
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $16.31B
See more insights into MRNA stock on TipRanks’ Stock Analysis page.
